- Home
- BTOG vs TCRT Comparison
BTOG vs TCRT Comparison
Compare BTOG & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTOG | TCRT |
|---|---|---|
| Founded | 2018 | 1998 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6M | 5.7M |
| IPO Year | 2018 | 2025 |
Fundamental Metrics
Financial Performance| Metric | BTOG | TCRT |
|---|---|---|
| Price | $2.72 | $2.72 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 96.9K | 10.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | N/A | $5,680,500.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $1.31 |
| 52 Week High | $5.96 | $5.48 |
Technical Indicators
Market Signals| Indicator | BTOG | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 50.37 |
| Support Level | $2.59 | $2.50 |
| Resistance Level | $2.97 | $2.73 |
| Average True Range (ATR) | 0.39 | 0.19 |
| MACD | -0.15 | 0.03 |
| Stochastic Oscillator | 18.94 | 98.00 |
Price Performance
Historical ComparisonAbout BTOG Bit Origin Limited
Bit Origin Ltd is seeking opportunities in deploying new technologies, crypto asset mining and blockchain technologies in Singapore. The company has focused on building the Bitcoin mining ecosystem through incubations, strategic investments, and acquisitions. It derives all of its revenue from Bitcoin mining.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.